Stocks · News reference
Cellectis Q2 Adj. EPS $(0.19) Beats $(0.27) Estimate, Sales $6.904M Miss $13.225M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 13.64 percent increase over losses of $(0.22) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:32 PM
- Checked
- Aug 6, 2026, 8:32 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Cellectis shares are trading higher after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to lasmecabtagene timgedleucel
Read original at benzingaCellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug
Read original at benzinga